Maze Therapeutics, Inc. (MAZE)
32.58
+0.13
(+0.40%)
USD |
NASDAQ |
Oct 21, 16:00
32.53
-0.05
(-0.15%)
Pre-Market: 20:00
Maze Therapeutics Enterprise Value : 1.458B for Oct. 21, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 21, 2026 | 1.458B |
| October 20, 2026 | 1.450B |
| October 19, 2026 | 1.298B |
| October 16, 2026 | 1.177B |
| October 15, 2026 | 1.175B |
| October 14, 2026 | 1.105B |
| October 13, 2026 | 1.129B |
| October 12, 2026 | 1.187B |
| October 09, 2026 | 1.154B |
| October 08, 2026 | 1.086B |
| October 07, 2026 | 1.106B |
| October 06, 2026 | 1.116B |
| October 05, 2026 | 1.116B |
| October 02, 2026 | 1.116B |
| October 01, 2026 | 1.129B |
| September 30, 2026 | 1.158B |
| September 29, 2026 | 1.149B |
| September 28, 2026 | 1.140B |
| September 25, 2026 | 1.095B |
| September 24, 2026 | 1.104B |
| September 23, 2026 | 1.208B |
| September 22, 2026 | 1.225B |
| September 21, 2026 | 892.08M |
| September 18, 2026 | 899.30M |
| September 17, 2026 | 950.36M |
| Date | Value |
|---|---|
| September 16, 2026 | 976.73M |
| September 15, 2026 | 994.21M |
| September 14, 2026 | 1.019B |
| September 11, 2026 | 1.015B |
| September 10, 2026 | 1.027B |
| September 09, 2026 | 1.014B |
| September 08, 2026 | 1.113B |
| September 04, 2026 | 1.104B |
| September 03, 2026 | 1.085B |
| September 02, 2026 | 1.132B |
| September 01, 2026 | 1.122B |
| August 31, 2026 | 1.124B |
| August 28, 2026 | 1.172B |
| August 27, 2026 | 1.237B |
| August 26, 2026 | 1.291B |
| August 25, 2026 | 1.338B |
| August 24, 2026 | 1.292B |
| August 21, 2026 | 1.283B |
| August 20, 2026 | 1.255B |
| August 19, 2026 | 1.301B |
| August 18, 2026 | 1.266B |
| August 17, 2026 | 1.201B |
| August 14, 2026 | 1.158B |
| August 13, 2026 | 1.185B |
| August 12, 2026 | 1.177B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.894B |
| Corcept Therapeutics, Inc. | 12.25B |
| Veru, Inc. | 16.11M |
| Johnson & Johnson | 647.93B |
| Eli Lilly & Co. | 1.242T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -44.73M |
| Total Expenses (Quarterly) | 44.73M |
| EPS Diluted (Quarterly) | -0.7581 |
| Earnings Yield | -7.78% |
| Normalized Earnings Yield | -7.786 |